Clinical Trials in Atlanta

Showing 6781-6800 of 19,805 trials

Biomarkers for Event-driven PrEP Adherence

NCT04298697

This study aims to recruit 40 participants who will take the combination anti-HIV drug tenofovir+emtricitabine (TDF/FTC) at specified times. Participants will then provide biologic samples for the measurement of anti-retroviral drug concentrations in various body compartment sites. Participants will be involved in the study for up to 24 weeks.

Human Immunodeficiency Virus

Emory University43 participantsStarted Feb 2020

Atlanta, Georgia, United States

COMPLETEDPhase 3< 1 mile

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)

NCT04576988

The objectives of this study are to evaluate the efficacy and safety of sotatercept (MK-7962) treatment (plus background pulmonary arterial hypertension (PAH) therapy) versus placebo (plus background PAH therapy) at 24 weeks in adults with PAH. The primary hypothesis of the study is that the participants receiving sotatercept will have improved 6-minute walk distance (6MWD) at 24 weeks compared to participants receiving placebo.

Pulmonary Arterial Hypertension

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA324 participantsStarted Jan 2021

Phoenix, Arizona, United States • Phoenix, Arizona, United States • Tucson, Arizona, United States +117 more locations

Biomarkers for Event-driven PrEP Adherence

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)

Find Trials by Condition in Atlanta

Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

Breethe Abiomed Recovery RegisTry (BART)

LCI-HEM-SCD-ST3P-UP-001: The Sickle Cell Trevor Thompson Transition Project (ST3P-UP Study)

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease

A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST

Evaluating Patients With Impaired Hepatic Function

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors

Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER)

Ammonia N-13 Myocardial Blood Flow Absolute Quantification by PET in Patients With Known or Suspected CAD (Ammonia MAP)

Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer

A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors